<DOC>
	<DOCNO>NCT00562107</DOCNO>
	<brief_summary>The aim study assess benefit AAISafeR/SafeR algorithm Symphony 2550 REPLY DR wide range pacemaker patient . The expected benefit result reduction percentage ventricular pacing . It contribute longevity cardiac pacemaker effect incidence sustain ( persistent ) Atrial Fibrillation Heart Failure . These clinical benefit result spontaneous ventricular activation ensure physiological ventricular activation . The benefit assess compare incidence atrial arrhythmias evolution haemodynamic status patient ( QOL , echo BNP )</brief_summary>
	<brief_title>Evaluation SafeR Mode Patients With Dual Chamber Pacemaker Indication</brief_title>
	<detailed_description />
	<criteria>Patient primoimplanted Symphony 2550 Reply DR le 1 month accord official guideline . Patient implant sinus node dysfunction ( include bradycardiatachycardia syndrome ) 2nd , advance 3rd degree intermittent allegedly permanent AV block . Patient implant bipolar right atrial lead right ventricular lead Patient sign consent form receive appropriate information Patient permanent AF Patient suffering sustain ventricular arrhythmia Patient congenital complete heart block Patient vasovagal syncope , carotid sinus syndrome Patient AV node ablation Patient suffer myocardial infarction within last month Patient suffer severe aortic stenosis Patient suffer unstable angina pectoris Patient able understand study objective protocol refuse cooperate Patient available schedule followup Patient life expectancy le one year Patient include another clinical study Patient minor , &lt; 18 year Patient pregnant woman Any patient contraindication device label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Minimized ventricular pacing , clinical outcome , SafeR , AAIsafeR , dual chamber pacemaker therapy , % ventricular pacing , hospitalization , symptomatic AF</keyword>
</DOC>